CTLA4 and neoplasm: Anti-CTLA-4 siRNA-loaded nanoparticles were efficiently internalized by TILs (4–6%) after systemic distribution, resulting in tumor growth reduction and longer survival in B16 F10 melanoma-bearing mice.